BCM
SABSW icon

Bluefin Capital Management’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Bluefin Capital Management’s Portfolio SABSW Stock Details SABSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-19,249
Closed -$34K – 943
2021
Q4 		$34K Buy
+19,249
New +$35.3K ﹤0.01% 721

Other funds holding SABSW

LP
LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.95% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bluefin Capital Management's SABSW Position: Q1 2022 in Review

Bluefin Capital Management sold out of SAB Biotherapeutics Warrant (SABSW) in Q1 2022, closing a stake of 19,249 shares — an estimated $34K sold.

Bluefin Capital Management first reported a position in SABSW in Q4 2021 and held it in 1 quarter. The position peaked at $34K in Q4 2021. 13 funds tracked by Wall St. Rank hold SABSW as of Q1 2022.

  • Bluefin Capital Management reported no remaining SAB Biotherapeutics Warrant position as of Q1 2022 after selling out during the quarter.
  • Bluefin Capital Management sold 19,249 SAB Biotherapeutics Warrant shares in Q1 2022, an estimated $34K.
  • Bluefin Capital Management first reported a position in SAB Biotherapeutics Warrant in Q4 2021 and held it in 1 quarter.
  • Bluefin Capital Management's SAB Biotherapeutics Warrant position peaked at $34K in Q4 2021.
  • 13 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q1 2022.

Based on Bluefin Capital Management's 13F filing for Q1 2022, filed 16 May 2022.